Skip to Content

Fenofibrate use while Breastfeeding

Drugs containing Fenofibrate: TriCor, Lofibra, Triglide, Antara, Lipofen, Lipidil Supra, Fenoglide, Lipidil Micro, Lipidil EZ

Medically reviewed by Drugs.com. Last updated on Oct 20, 2020.

Fenofibrate Levels and Effects while Breastfeeding

Summary of Use during Lactation

No relevant published information exists on the use of fenofibrate during breastfeeding. Because of a concern with disruption of infant lipid metabolism, fenofibrate is best avoided during breastfeeding. An alternate drug is preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be avoided during fenofibrate therapy and for 5 days after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Cholestyramine, Colesevelam, Colestipol

Substance Identification

Substance Name

Fenofibrate

CAS Registry Number

49562-28-9

Drug Class

  • Breast Feeding
  • Lactation
  • Anticholesteremic Agents
  • Antilipemic Agents
  • Fibric Acids

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.